Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Interpace Biosciences Inc (IDXG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -6.503x
Based on the latest financial reports, Interpace Biosciences Inc (IDXG) has a cash flow conversion efficiency ratio of -6.503x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.94 Million) by net assets ($-298.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Interpace Biosciences Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Interpace Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Interpace Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Interpace Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DONTNOD Entertainment SA
PA:ALDNE
|
-0.071x |
|
Pila Pharma AB
ST:PILA
|
-0.129x |
|
Digistar Corporation Bhd
KLSE:0029
|
0.010x |
|
CopperEx Resources Corporation
V:CUEX
|
-0.006x |
|
Tactical Resources Corp.
PINK:USREF
|
0.002x |
|
MBB (MBB.SG)
STU:MBB
|
-0.018x |
|
Merino & Co. Ltd
AU:MNC
|
-0.349x |
|
Mint Corp
V:MIT
|
0.055x |
Annual Cash Flow Conversion Efficiency for Interpace Biosciences Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Interpace Biosciences Inc from 2000 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.22 Million | $4.65 Million | -2.096x | -3310.96% |
| 2023-12-31 | $-61.67 Million | $3.79 Million | -0.061x | -150.38% |
| 2022-12-31 | $-63.07 Million | $-7.69 Million | 0.122x | +105.76% |
| 2021-12-31 | $4.12 Million | $-8.72 Million | -2.117x | -164.35% |
| 2020-12-31 | $17.45 Million | $-13.98 Million | -0.801x | +8.35% |
| 2019-12-31 | $21.69 Million | $-18.96 Million | -0.874x | -231.88% |
| 2018-12-31 | $32.94 Million | $-8.67 Million | -0.263x | +31.22% |
| 2017-12-31 | $39.87 Million | $-15.26 Million | -0.383x | +72.03% |
| 2016-12-31 | $6.53 Million | $-8.94 Million | -1.369x | +10.05% |
| 2015-12-31 | $13.04 Million | $-19.84 Million | -1.522x | -86.98% |
| 2014-12-31 | $20.12 Million | $-16.38 Million | -0.814x | -652.73% |
| 2013-12-31 | $32.48 Million | $-3.51 Million | -0.108x | +62.54% |
| 2012-12-31 | $35.63 Million | $-10.29 Million | -0.289x | -965.68% |
| 2011-12-31 | $59.52 Million | $1.99 Million | 0.033x | -85.82% |
| 2010-12-31 | $69.51 Million | $16.35 Million | 0.235x | +78.29% |
| 2006-12-31 | $149.20 Million | $19.68 Million | 0.132x | +474.39% |
| 2005-12-31 | $135.61 Million | $3.12 Million | 0.023x | -86.89% |
| 2004-12-31 | $165.43 Million | $28.98 Million | 0.175x | -41.72% |
| 2003-12-31 | $138.49 Million | $41.63 Million | 0.301x | -43.37% |
| 2001-12-31 | $150.94 Million | $80.13 Million | 0.531x | +283.72% |
| 2000-12-31 | $138.11 Million | $19.11 Million | 0.138x | -- |